8GT-15231-22731
2 vaccinations
1 coded response
20 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 781 / TX
- Registered
- 2021-10-29
- Relationship
- Self
- Race
- Black or African American
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-10-29
Registered in v-safe
-
2021-10-29
Dose 1 — Pfizer-BioNTech
- 2021-10-29
- 2021-10-30
- 2021-10-31
- 2021-11-05
- 2021-11-14
-
2021-11-19
Dose 2 — Pfizer-BioNTech
- 2021-11-19
- 2021-11-20
- 2021-11-22
- 2021-11-23
- 2021-11-24
- 2021-11-25
- 2021-11-26
- 2021-12-03
- 2021-12-10
- 2021-12-18
- 2021-12-24
-
2021-12-31
Survey response — day 42, dose 2MedDRA: Headache, Oropharyngeal pain, Paranasal sinus discomfort, Pyrexia, Rhinorrhoea — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Sore throat, runny nose, sinus pressure, fever and headache.MedDRA releases: 2024-11 · check-in free text available
- 2022-02-18
- 2022-05-20
- 2022-11-21
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-10-29 | Pfizer-BioNTech | No |
| 2 | 2021-11-19 | Pfizer-BioNTech | No |
Free text
Release 10 — day 42, dose 2
Symptoms: Sore throat, runny nose, sinus pressure, fever and headache.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Headache | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Paranasal sinus discomfort | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release